Marissa Brittenham
Known title: Chief Strategy OfficerCIK: 0001908044
Associated companies
Transaction History
| SGRY | ▼ Sell | Open Market | 3,657 | $46K | 3/13/2026 | View on chart |
| SGRY | ▼ Sell | Open Market | 8,785 | $120K | 3/6/2026 | View on chart |
| SGRY | ▲ Buy | Grant | 17,717 | $250K | 3/5/2026 | View on chart |
| SGRY | ▲ Buy | Grant | 16,363 | $231K | 3/5/2026 | View on chart |
| SGRY | ▲ Buy | Grant | 9,150 | $129K | 3/5/2026 | View on chart |
| SGRY | ▼ Sell | Open Market | 3,156 | $76K | 3/10/2025 | View on chart |
| SGRY | ▲ Buy | Grant | 10,084 | $240K | 3/4/2025 | View on chart |
| SGRY | ▲ Buy | Grant | 6,302 | $150K | 3/4/2025 | View on chart |
| SGRY | ▼ Sell | Open Market | 14,700 | $376K | 2/7/2025 | View on chart |
| SGRY | ▲ Buy | Grant | 25,110 | $0 | 1/31/2025 | View on chart |
| SGRY | ▼ Sell | Open Market | 1,284 | $39K | 3/4/2024 | View on chart |
| SGRY | ▲ Buy | Grant | 2,886 | $90K | 2/28/2024 | View on chart |
| SGRY | ▲ Buy | Grant | 7,697 | $240K | 2/28/2024 | View on chart |
| SGRY | ▼ Sell | Open Market | 1,637 | $52K | 2/2/2024 | View on chart |
| SGRY | ▲ Buy | Grant | 7,608 | $250K | 3/2/2023 | View on chart |
| SGRY | ▲ Buy | Grant | 15,216 | $500K | 3/2/2023 | View on chart |
| SGRY | ▼ Sell | Open Market | 1,320 | $47K | 2/2/2023 | View on chart |
| SGRY | ▲ Buy | Grant | 10,602 | $475K | 2/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
SGRY Volumes Soften as Analysts Debate Valuation
Surgery Partners is experiencing lower trading volumes while analysts continue to debate its value. Recent reports note a significant five-year decline, yet some estimates suggest the stock is still below fair value. The company remains a point of interest within the Russell 2000, with mixed views on its competitive position and future challenges.
SGRY Volumes Soften as Analysts Debate Valuation. Surgery Partners is experiencing lower trading volumes while analysts continue to debate its value. Recent reports note a significant five-year decline, yet some estimates suggest the stock is still below fair value. The company remains a point of interest within the Russell 2000, with mixed views on its competitive position and future challenges.